Brief: Pharmacyte Biotech Enters License Agreement For Covid-19 Diagnostic Kits
08/04/2020 12:51
April 8 (Reuters) - PharmaCyte Biotech Inc PMCB.PK :
* PHARMACYTE BIOTECH ENTERS INTO LICENSE AGREEMENT FOR
COVID-19
DIAGNOSTIC KITS
* PHARMACYTE BIOTECH- ENTERED INTO A LICENSE AGREEMENT WITH
HAI
KANG LIFE CORPORATION LIMITED
Source text for Eikon: ID:nBw6T2ZNWa
Further company coverage: PMCB.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmacyte Biotech
See all newsBrief: Pharmacyte Biotech Inc - Increases Stake In Tnf Pharmaceuticals By $3 Million
Brief: PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
Brief: Pharmacyte Biotech Acquires $5 Million Stake In Emerging Women’S Health Innovator Femasys
Brief: Femasys Inc. Secures Additional Financing With Strategic Investment From Investors Led By Pharmacyte Biotech
Brief: Pharmacyte Biotech Announces Final Results Of Tender Offer